Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Polsinelli hires ‘valuable asset’ for Denver office
Careers
Experienced patent attorney represents clients in a wide range of industries, including renewable energy, semiconductors and artificial intelligence.   21 May 2024
Teva targets Indian pharma firm over asthma inhaler patents
Pharma
Asthma is one of the most common respiratory diseases in the US and the most common chronic disease among children | Israeli pharma giant’s suit comes amid allegations that it keeps life-saving prescriptions treatments artificially high.   7 May 2024
Pharmacy defends Eli Lilly off-label drug suit
Pharma
Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro.   11 April 2024
Pharma
Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion | Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan.   9 April 2024
Generics
Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.   28 March 2024
article
The firm has appointed a leading attorney and a prosecutor to jointly lead its new division.   13 February 2024
Americas
Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report.   8 February 2024
Biotech
Biotech claims action was necessary due to unfavourable rulings after being targeted by a rival | Accuses gene technology firm of attempting to shrink the competitive landscape for different spatial biology platforms.   6 February 2024
Biotech
SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.   11 January 2024
Pharma
Generics companies have often inveighed against the “arbitrary and capricious” rule | Judicial immunity granted to Vidal’s decisions at odds with Congress and SCOTUS precedent, say generics and big tech.   9 January 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.